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Cytotoxic T lymphocytes raised against a
subdominanl epitope offered as a synthetic
peptide eradicate human papillomavirus type 16-
induced tumors
Previously, we have shown that immunization with human papillomavirus
(HPV) type 16-derived cytotoxic T lymphocyte (CTL) epitope E7 <W-57
(RAHYNIVTF) renders C?7BL/6mice insensitive to tumors formed hy HPV16-
transformed cells. In this study, we provide evidence that E7 49-57 is expressed
as a subdominanl CTL epitope on HPVI6-transformed C57BL/6 cells. Using
acid peptide cliilion, it is shown that HPV16-transformed tells express another
CTL epitope. besides E7 49-57, which appears to he dominant. We demonstrate
that a CTL line raised against the subdominant CTL epitope. offered as synthe-
tic peptide E7 49-57, eradicates established. HPV16-mduced tumors in mice.
Our data show that synthetic peptide-induced CTL can be applied successfully
in vivo against (virus-induced) tumor, and emphasize thai subdominant CTL
epitopes are useful targets for immunothcrapy. Furthermore, it is illustrated for
the first time that HPV In-specific CTL interfere directly with HPVIft-indueed
tumors.
1 Introduction
Human papillomavirus (HPV) type 16, in particular the
Viral oncogene products E6 and È7, arc believed to piuy a
causative role in cervical cancer f l j , Development of
HPV16-associated (pre)malignant lesions is enhanced in
individuals with impaired T ceJI responses J2-5J, suggest-
ing that cellular immunity impedes HPV Ift-associated
tumor development, CTL are important effectors of pro-
tection against (virus-induced) cancer [6, 7|. They lyse tar-
get cells upon recognition of specific peptides presented at
the cell surface by MHC class 1 molecules |8j. In the case
of virus-infected cefls, these peptides originate mainly
from rntraceJlular viral proteins [9, 10J, which are
degraded in the cylosol and bound specificaMy by class I
MHC molecules, followed by transport to the cell surface
[11].
Previously, we have identified an MHC dass, I H-2Dh-
binding peptide, HPVJ6 E7 49-57 {RAHYNIVTF), that
elicited CTL responses in C57BU6 (B6) (H-2h) mice f 12].
Vaccination with synthetic peptide E7 49-57. either mixed
with 1FA [12] or loaded on dendritic cells [32|. specificaMy
prevented tumor formation by HPVKvtransformed Eifi
mouse embryo cells (MEC) (C3 cells). Protection was
associated with expansion of peptide-specific CTL. which
upon stimulation from memory cells, were capable of lys-
ing C3 cells in vitro [12], presumably as the result of spe-
cific recognition of peptide E7 49-57 presented by class t
MHC H-2D" molecules on the tumor cell membrane.
Therefore, CTL raised against synthetic peptide E749-57
should be'able to rccogni/e naturally processed E7 49-57
peptide expressed: on HPV 16-transformed C3 cells and
cure established C3 tumors when injected in tumor-
beartng B6 mice.
In this study, we describe ïhe generation and characteriza-
tion of a stable CTL line raised against synthetic peplidc
E7 49-57. This CTL line specifically recognizes E7 4^-57
as a naturally processed peptide on HPV]6-transf:>nned
C3 ce3ls and eradicates established O tumors in Bn nude
mice, in addition, we show that OTL epitope E7 49-57 is
immuno-subdominantJy expressed on C3 cells, inasmuch
as CTL raised against C3 cells recognize another naluralK'
processed; peptide. The data prestrnled in this study are the
first esampJes of CTL-based immunotherapy against
established HPVI6-induced tumors, supporting the
thought that T cells are involved in the control of cer-
vical cancer. Furthermore, our data stress the feasibility of
generating tumor-specific CTL againsl epitopes of choice,
in particular subdomrnant epiiopes, offered as synthetic
peptides.
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2 Materials and methods
2.1 Cell Hues, gi'iieralkin al CTL lints/clones and culture
cünditJons
Cell line C3 wasohtainetï frctrn HPV36-/EJrfis-transformcd
B6MEC J12|. and cell line Xhoc3 from udenovtnis type S
(Ad5) El-transformed B6MHC |!3|. Cell line p«" was
obtained from HPVI6-transformcc! BfiMEC. In contrast
to C3 cells, pK cells do not form tumors in Bft mice. Cell
line EL4 is derived from Bn thymoma cells [I4|. All cells
were cultured in Iscove's modified DMEM supple-
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;i| O: HPVId/EJriis-trsmliH-med B6 MKC.
h) Xhoc.l: Ad5 Ht-tnitisfntmed B6 MEC
c) pS: HPVIMrjnsfarnKd Bh M EC.
d j Effector li> target ratio.
e) Percentage specific lysis. The ex peri mem shown is :i representative of ik independent
exceeded i l l 'ii»n1' the c;ilciiliUcd m CM n percentage specific lysis, which is depicted.
s. SDof iriplit
merited with HCS, antibiotics and 2-ME. as described [ 1 2 ] .
CTL l ine FaO wa-% made by immunizing Bh mice s,c. with
11)0 ug synlhetic H7 4ü-57~ peptide mixed with I FA [12].
After 14 days. T cell-enriched spleen cells [15] were cul-
tured in t IK presence ol E7 49-57 peptide-loaded RMA-S
cells (50 JIM. 2 li in serum-free medium) [ 15, J6j tn %-wdl
plates. 2 x 1(T and 5 x II)4 cells/well, respectively After
5 days, viable cells w-eie stimulated weekly wi th (KN-y-
pretreated ( U) t l J /ml . 4S h) C"3 cells. From d;w 12 on, the
equivalent of WJ RJ/m] rlL-2 derived from the supernatant
of C "on A-lreated rat spleen cells was added to the cul tures
[17|. w h ich was gradually replaced hy 2IKJ ID/ml rlL-2
from week X onwards. Using limiting J i l u i i o i CTL clone
7C!1 was obtained from Bti mice immunized with \fr 1FN-
y-pretrcated C'3 cells, inactivated by irrwdiation. suspended
in 2(KI u t |»BS, and injected s.c. twice with a 2-week inter-
val. CTL clone ( I I . specifically recot-ni/ing peptide Ad5
EIB I92-ÏÏM». was raised against" mutunl Ad? E J -
trynsiormed IM* MHC 1I8|. CTL clones 7G I and (II were
st imulated weekly with IFN-y-pietrealed C3 and Xho3
cells, respectively, in the presence of 5(1 ILÏ/ml rlL-2. All
CTL were CD4 CDS . as demonstntted by FACS {data
not shown L
2.2 Europium (Ku1+|-rcleas* cvtiitnxicity assay
Eu n ! labeling and tif'-release assay were performed as
described 112, 19j. In the ease of peptide loading, labeled tar-
pet cells wen? incubated wi lh 0.5 JIM peptide prior to addiïion
10 the effector cells. Alter 4 h ui 37nC. supernatanls were ana-
tyicd in a I2.*U Dclftt" tluLmimeter (Wallae. Turku. Finland ].
The mean percentage specific hit' Ttlease of triplicate wells
was calculated as follows: % specific lysis - {cpm cspt'rimen-
tal release • cpm spontaneous releasc)/(cpm maximum
Fele;ise - cpm spontaneous release) x HKL
2.3 Add peptide elutiim
Aeid peptide eÊution was performed as described [20. 21], CTL line FaC3, induced against synthetic peptide HPVlri
with slight modifications. IFN-y-preïreated C3 cells E7 49-57 and stable in culture for more than i year, was
(3 x 10'; Kl [U/ml. 48 h| were washed and incubated with
5 ml acid huffer solution ((1.131 M citric acid, 0.06! M
Na;HPO4 • 2H:O. pH 3-3} for 3 min at room temperature.
Peptides in the supernatant of 8 x JO" cells were concen-
trated and desalted on a Sep-pak CIS column (Millipore.
Milford, MA}. Peplide malerial was eluted with 1 mi of
00% acetoniirile in H:O. lyophilized and dissolved in M K I
N! H:O. The reeonsiituted material was fractionated using
an aeetonitrile gradient on a CIS re verse-phase HPLC'
column (Pharmacia LKB. Roosendaal. The Nether lands) .
I nd iv idua l fractions were lyophili/ed. reconstituted with
PBS to 100 [d and analyzed in a Eu'1-release assay Fur
each CTL tested, three wefls wi th 5 |d/wcll of each fraction
were incubated with En' -labeled EL4 cells for 3() msn
liefore CTL were added.
2.4 Mice and aduptive transfer
T cell-deficient Bft nude mice (Bolmholtyard. Ry. Den-
mark}, held under specific iiathogen-free conditions ;ii
TNO-PG {Leiden. The Netherlands), were inoculated s.e.
each with 5 x id" O cells at the right Hank. When tumors
were about 200 mm', therapy was started via adoptive
transfer of 25 x 10" CTL injected i.v. in the tail vein or
intFaturnorally ( i . t . ) directly into the tumor in 300 |d or
50 )it ceil suspension, respectively. This was repeated
weekly for 3 weeks and combined with s.c. administration
of HI' IU rlL-2 in IFA an the left f lank. THe same amount
of 1L-2 was also given every .Vd day a l ïer CTL injection.
3 K e suits
3.1 Synlhelie peplidc HPV16 E7 49-57-indueed CTL
«p«nflca(lv \yse E7 49-57 peptidc-loaded KLA cells as
well as HPVlrVtransfurmed C3 cell*
M.C. W Felikampetal
HPLC-Mp»™t«d C3 P*p1 d*
figure J. HPV16 E7 4Y-57 pcpiide-induced CTL and C3 cell-
induced CTL, respectively, recognize different HPLC-sepamtct!
peptide fractions derived From acid-duted HPVl6-Transformed
C3 cells. Peplide material from the supernatant of a Io(a1 of
8 x Id1* acid (pH 3.3) burïer-treated C3 cells was separated hy
reverse-phase (Cf£) HPLC A proportion of each fraction was
incubated with Eu'"-labcledEL4 cells, after which either the E7
49-57 synthetic peptide-induced CTL line FaC3 or C3 cell-
induced CTL clone 7G1 was added. A standard E u u -re lease assay
was carried out, followed by calculation of the percent specific
lysis A representative experiment out of three is shown.
Eur. J. Immunot. 1995, 23: 2638-2642
3.2 HPVló~transfurnied C3 cell-induced CTLspecificaJly
hst- HPVHV-trunsiFtriTK'd C3 cells but do not lyse £7
49-57 peptide-loaded I'.IA cells
In Ihe same experiment, CTL obtained from HPVI6-
transformed C3 cell-immunized: mice were tested. CTL
clone 7G1. a representative of many CTLbuïks and clones
obtained from several independent C3 cell immunizations
over the years (one of which was described before [23]).
specifically iysed C3 cells. Surprisingly, E7 49-57-pulsed
EL4 cells were no! lysed by 7GÏ (Tabie I), suggesting that
HPVlfc-transformed C3 cells express at least two CTL epi-
topes. Of these two epitopes, E7 49-57 is subdominant in
the sense that upon C3 cell immunization (in contrast to
E7 49-57 peptide vaccination), no CTL were detected; thai
recognize this particular peptide. The HPV ló-transformed
B6 MEC line p8, which does not contain EJras, was also
•iysed by 7GI, implying that the immunodominant epiiope
expressedon C3 cells is HPV16specific (Table l). SirniJar
target cell recognition patterns were observed when spe-
cific TNF-a release by the CTL tested was monitored (data
not shown).
tested for target cell recognition. In a representative exper-
iment, FaC3 specifically Jysed syngeneic EL4 cells pulsed
with E7 49-57 peptide, as well as C3 cells that express the
HPVIÓ E7 gene [12] (Table 1). EL4 ceils loaded with the
Derestricted CTL epitope AdS E1B 192-200 as well as
Ad5 El-transformed B6MEC <Xhoc3 celb) were not lysed
by FaC3. whereas they were by AÖ5 El B 192-200-specific
CTL clone 01 [18] {Table i). In titration experimems, the
affinity of FaC3 for its cognate peptide was lost between JO
and l pM (daïa not shown), which is comparable wilh
other known murine CTL clones [18, 22].
Qay-t attar aten of CTL trMtm«n!
Figure 2. Entratumural administration of HPVI6 E7 49-57-
specific CTL line FaC3 eradicates tumors induced hy HPV 1ft-
tran&formedC3ceJls inTcell-deficient Bü nude mice The results
shown are from a representative experiment of two. in which Bft
nude mice were inoculated s.c. with 5 x 10" HPVlft-transformed
C3 cells. When tumors of about 200 mm3 were formed, mice were
injected i.t. weekly for 3 weeks (closed arrows) with 25 x J0fi
HPV16 E7 4y-57-specific CTL line FaC3 (closed circles, it = 4) or
25 x 10s Ad5E3B 192-200-specific CTL clone 01 (apen circles, n
= 4). At the same time, the mice received 10' IU ÏLL-2 s.c.. which
was repeated 3 days after each CTL injection (open arrows), The
tumor volumes are shown from the first day of CTL treatment
onwards.
3.3 Different peptide fractions obtained from HPV16-
Iransformed C3 cells are specifically recognized In
E7 49-57 peptide-induced CTL and C3 cell-induct
CTL, respectively '
To show-that HPV16-transformed C3 cells express at least
two different CTL epitopes, among which is E7 49-57, we
subjected 8 x Iff cultured C3 cells to mild acid treatment.
As a result, peptides are eluted from cell surface MHC
class I molecules J21]. This preparation was fractionated
by reverse-phase HPLC. Individual fractions were ana-
lyzed for their ability to sensitize EL4 cells to lysis hy E7
49-57 peptide-induced CTL line FaC3 and C3 cell-induced
CTL clone 7G1. respectively. Fractions 17 and 1& sensi-
tized EL4 cclb for lysis by E7 49-57 peptide-spetific CTL
line FaC3 {Fig. 1), indicating (hat subdominant epitope E7
49-57 is presented on the cell membrane of C3 cells. Frac-
tions 15 and 16 were recognized speciflcalJy by CTL clone
7GL proving that C3 cells express at least one other CTL
epkope besides E7 49-57.
3.4 CTL raised against immimo-subdominant CTL
epitope E7 49-57 eradicate HPVIA-inducvd C3
s in vivo
Finally, we investigated whether CTL line FaC3. raised
agains! subdominant CTL epitope E7 49-57 offered as
synthetic pepiide, was able to eradicate established C3
tumors in vivo. T cell-deficient B6 nude mice with estab-
lished C3 tumors of about 200 mm1 were injected weekly
with 25 K !(ƒ cultured FaC3 cells, administered either i.v.
or i.t. in combination with 10s JU riL-2 s.c. As specificity
control, a group of mice was included that received Ad5
ElB-specific CTL clone 01 i.t. in combination with 1L-2
s.c. Another group of mice received only 1L-2 s.c. In two
independent experiments (two and four mice per group,
respectively), a total of six out of six mice treated with
FaC3 i.t. plus IL-2 s.c. were cured of C3 tumors within 3
weeks (Fig. 2). In the mice receiving IL-2 s.c. only, six out
of six (umors grew progressively (data not shown),
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This was also observed in each of four mice that were
treated with CTL clone 01 i.t . plus LL-2 s.c. (Fig. 2). The
latter combination is known to eradicate AdS-induced
tumors ir B6 nude mice [18], Although a turnor growth
delay was observed in four of six mice, only one of six mice
was cured from its C3 tumor following FaC3 i.v. plus 1L-2
s.c. administration (data not shown).
4 Discussion
We have shown that CTL induced against synthetic pep-
tides representing a suhdomirianl epitope recognize the
naturally processed counterparts on turnor cells.
Expressed on C3 cells, peptide E7 49-57 h nol immuno-
gcnic, inasmuch as CTL induced by O cells recognize
another C3 cell-presented peptide instead (Fie- i and Ta-
ble 1) . Whether E7 49-57 is not immunogenic^ai aJI when
expressed on C3 ceils cannot be concluded from the ex-
periments shown. Expressed on C3 cells, subdominant
epitope E7 49-57 is antigcnic, since CTL induced against
E7 49-57, necessarily offered as a synthetic peptide, spe-
cifically recognize C3 ccJIs (Table 1 and Fig. 1). It rs of
interest lo note that E7 49-57 is immunogenic when pre-
sented on H-2h cells infected with recombinant vaccinia
virus expressing HPVI6 E7 (24j. Since the E7 protein
expression ievcl is probably higher in HPV16 E7-
expressing vaccinia virus-infected cells than in HPV16-
iransformerj O cells, the imrnunogenicily of peptide E7
49-57 is presumably determined by the level of E7 expres-
sion. It is known thai protein expression levels correlate
with the amount of protein-derived peptidcs thai occupy
specific MHC class 1 molecules |25j, and thai higher
expression levels of MHC class I-botind peplidcs are
needed for CTL induction (immunogenidty) than for CTL
recognition (antigenicity) [2fi]. We are currently investigat-
ing ihe nature of the immunodominant CTL epitope, the
recognition of which is H-2D1' restricted (data not shown).
Since C3 ceHs express at least the E5, En and E7 open
reading frames (|12| and data not shown), ihe peptide may
be associated with any of these HPVlo proteins.
CTL fine FaC3 was induced in vivo by E7 49-57 synthetic
peptide vaccination, followed by reslimulatfon in vitro
with E7 49-57 peptide-pulsed RMA-S cells. It cannot be
excluded, however, that FaC3 was obtained from primary
CTL, induced in w'lw since it is known that peptide-loaded
RMA-S cells are able to induce such a response f26]. After
5 days, the E7 49-57 peptide-induced CTL huïk culture
was stimulated with C3 cells instead of with E7 49-57
peptide-pulsed RMA-S (or other syngeneic) cells. This
seemed obligatory, since repetitive stimulation with
peptide-pulsed cells resulted in the loss of CTL (multiple
unpublished observations). We believe that this loss corre-
lates with the concentration of peptide wilh which the
stimulator cells are inciibaïed {unpublished observe lions).
CTL directed against immunogenic (dominani) peptide»
presented ai (he eel! surface of tumor cells are known to
eradicate lumors |13, IS. 27. 2H|. Our data show, for the
first time, that CTL directed against a suhdominant CTL
epitope can be useful for cancer therapy. These findings
are valid for tumor eradication by CTL infusion (this
study) as well as for tumor prevention by synthetic peptide
vaccination [12|. Peptide-induced CTL may have
additional value over whole tumor cell-induced CTL. in
the sense that the target peptides do not necessarily need
to be immunodominanl CTL epitopes. In principle, CTL
can be raised against a number of {subdominant) epitopes
represented by synthetic peptides, thereby diminishing the
ehance of CTL escape variants to occur. We have indica-
tions lhat primary synthetic peptide E7 4u-57-specific
CTL that are induced in vitro also eradicate tumors in vivo
{unpublished observations)- Of general importance could
be the knowledge that (rumor) cells do nol necessarily
need to express immunogenic peptides, to be sensitive to
CTL therapy.
CTL line FaC3 eradicated C3 tumors in six out of six mice
that received FaC3 i . t . , whereas after i.v. administration
eradication was observed in only one of six mice. Possibly,
when injected i.v. under the conditions use<5, the number
of FaC3 actually arriving at the tumor site was too low to
cope with this fast-growing tumor. Only when iargc num-
bers of FaC3 were injected directly into the C3 tumor
could an adequate E/T radio eould be reached in vivo,
resulting in tumor destruction. Interestingly, the tumor
size of the one mouse that was cured from its tumor after
i.v. FaC3 administration, was the smallest of a l l CTL-
treated lumors at the start of treatment (60 mnv). Further
experiments are needed to determine whclher tumor size
is an important factor leading to failure or success of CTL
therapy. Alternatively, the homing properties of FaC3 may
not be of the same quality as those of previously reported
CTL clones that were abïe to eradicate tumors efficiently
upon i.v. infusion |J3, 18, 28], However, absence of hom-
ing is unlikeiy, since CTL with exactly ihe same specificity
as FaC3 can he grown from C3 tumors treated i.v. with
FaC3 (preliminary results).
The results presented in this study show, for the first time.
that HPVlf» E7-specific CTL are directly responsible for
the disappearance of HPV16-induced tumor tissue. In
another study in mice (C3H), although CTL specificity
was not determined, it was suggested that HPVI6 E7 acts
as a tumor rejection antigen for CTL }2U|. Our data are
also in agreement wi th studies showing that a correlation
exists between prevalence and progression of HPV(16)-
related proliferative disease and impairment of T celi
immunity |2-5]. Taken together, these observations justify
siudies. which propose to infuse HPVlft-specific CTL in
patients with HPVtft-induced {prejmalignan! lesions.
These approaches require the identification of HPVI6-
derived CTL epitopes that are naturally expressed in the
context of human MHC class I molecules |.KI, 31].
Although our study suggests that tumor eradication is only
to be expected following local infusion, pre l iminary data
show that upon therapeut ic E7 49-57 peptide vaccination
distant from the C3 tumor site, eradication of small lumors
(<50mm !) is observed (unpublished results). This indi-
cates that among the induced repertoire, peptide-specific
CTL are present lha t do home lo the tumor, suggesting
that circulating HPVIfY-spccific CTL are also ahlc to
eradicate HPVIfvinduccd tumors.
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Transplantation tolerance and T cel! regulation 2643
Transplantation tolerance induced by antigen
pretreatment and depleting anti-CD4 antibody
depends on CD4* T cell regulation during the
induction phase of the response
Adult mice pretrealed with do n or-spec i fie transfusion and depleting anti-CD4
antibody 28 days before transplant accept fuily allogeneic heart grafts and
become specifically tolerant without further treatment. The induction of toler-
ance in this model is not simply a function of CD4* T cell ablation, hut appears
to depend on residual CD4* T cells which escape depletion and engage donor
aHoanligen during a transient period of antibody blockade. To test the hypothe-
sis that these CD4* T cells might be responsible for regulating immune respon-
ses toward the graft, mice were reconstituted with naive recipient Leukocytes at
various times after pretreatment. Reconstitution either shortly after pretreat-
ment or shortly after transplant had little effect on graft survival. However,
when pretreated mice were given an additional dose of depleting anti-CD4 anti-
body at the time of transplant to target putative regulatory cells, naive leuko-
cytes were able to cause acute graft rejection. These data suggest that in clinical
transplantation specific T cell regulation might develop following pretrcatment
with antigen and non-depleting anti-CD-I antibodies. Such an approach could
provide donor-specific unresponsive r ess prior to transplant without the risks
associated with sustained CD4f T cell depletion.
l liitrn.liKïimi
CD4h T cells play a pivotal role in graft rejection and the
breakdown of self-tolerance in the development of autoim-
munity. A large number of experimental models h;tve
demonstrated that monoclonal antibodies which target this
T cell suhset can prolong allograft survival or inhibit the
onset of autoimmune disease [ 1-1(3}. In view of this, anli-
CD4 antibodies arc attracting increasing attention as clin-
icai Therapeutic agents [ IE-14) . hui if these reagents are to
be used lo maximum effect in man, it will be importani to
establish their precise mode of action.
In murine models, impressive graft prolongation can be
achieved using pcri-opcrativc administration of antibodies
which deplete CD4' T cells, hut in clinical transplantation
there may be a reluctance to use such antibodies at the
time of transplan! because the depletion they cause is pro-
found and long-lasting [13™ 15]. However, ïhese reagents
may have the potential far a much more subtïe manipula-
tion of immune responses in vivo as shown by the fact that
when mice arc prctrealcd with protein antigen under the
cover of anti-CI>4 antibody, they remain tolerant to the
original priming antigen even when the nonspecific effects
of the antibody trealmenl have decayed j tó-18J. Tolerance
induced by such combined pretrcatmcnt is antigen specific
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and can be maintained by repeated challenge with antigen
alone; no further antibody treatment is required. We have
translated this approach into a strategy for the induction of
tolerance to alloantigen in which recipient mice are pre-
treated with a donor-specific blood transfusion (DST)
under ihe cover of a depleting anti-CD4 antibody [19. 20).
This pretreatment regimen leads to indefinite cardiac
allograft survival in the majority of recipients and is inde-
pendent of any further immunosuppressive therapy. Graft
prolongation is donor specific and leads to operational
tolerance in the Jong-term, in that animals with surviving
heart grafts accept donor specific skin grafts but reject
those from a third party J20). We have investigated the
mechanisms responsible for aUograft survival in this model
and demonstrate that the induction of tolerance depends
on active immune regulation mediated by CD4J T cells.
Our observations support conclusions which could have fin
important impact on the way in which the powerful immu-
nosuppressive effects of anti-CD4 antibodies may he
exploited in clinical transplantation.
2 Materials and methods
2.1 Mice
Mice (C3H/He: H-2k and C57BL/K); B]fl. H-2I%) were
obtained from Harlan-Olac, Bicester, GR or the National
institute for Medical Research. Harrow, GB-
2.2 Anti-CD4anlibod>
The hybridoma YTA 3.1.2 [21] (kindly provided by Prof.
H. Waldmann). produces an lgG2b rat anti-mouse CD4
antibody which was prepared as ascites in (LOU x DA)F,
rats and purified by ammonium sulfale precipitation fol-
lowed by ion-exchange chromatography. Antibody purily
VCH Vcrkigünt'scllschafr mhH.
